All News
Filter News
Found 230 articles
-
EILEAN THERAPEUTICS DOSES FIRST PATIENT WITH ZE46-0134, A SELECTIVE FLT3wt-SPARING, PAN FLT3mut INHIBITOR
8/21/2023
Eilean Therapeutics LLC today announced the initiation of human dosing in the Phase 1 clinical program of ZE46-0134, a highly potent and selective pan-FLT3 inhibitor that targets clinically relevant FLT3 mutations including the FLT3 gatekeeper mutation, while sparing the wild type form of the protein.
-
ImmPACT Bio Announces FDA Clearance of IND Application for Bispecific CD19/CD20 CAR T Therapy IMPT-514 for the Treatment of Refractory Systemic Lupus Erythematosus
8/15/2023
ImmPACT Bio USA, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for IMPT-514, a bispecific CD19/CD20 CAR T therapy for the treatment of active, refractory systemic lupus erythematosus (SLE).
-
Sagimet Biosciences Announces Leadership Changes - July 20, 2023
7/20/2023
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced a series of leadership changes and appointments, designed to ensure a seamless transition into the next stage of growth for the company.
-
In its latest legal challenge to the Inflation Reduction Act, the U.S. Chamber of Commerce has appealed to a federal court to stop drug price negotiations until ongoing litigation plays out.
-
Tevogen Bio Welcomes Victor Sordillo, Renowned Global Safety Management Expert, to its Board of Directors
7/12/2023
Tevogen Bio Inc. is pleased to announce the appointment of safety management expert Victor Sordillo, PE, CSP, M.B.A., to its Board of Directors.
-
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
7/6/2023
NanoViricides, Inc. reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.
-
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
6/29/2023
Tevogen Bio Inc. and Semper Paratus Acquisition Corporation today announced the execution of a merger agreement (the “Merger Agreement”).
-
BostonGene Highlights Approach to IO Research and Precision Medicine at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference
6/20/2023
BostonGene Highlights Approach to IO Research and Precision Medicine at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference.
-
Medigene to Present Data Highlighting the Enhanced Tumor Cell Killing Effects of Adding the PD1-41BB Switch Receptor to Multiple TCR-T Therapies at the Immuno-Oncology Summit Europe
6/14/2023
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 7th annual Immuno-Oncology Summit Europe which will take place June 20-22, 2023 in London, UK.
-
Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection Applications for Translational Research and Precision Therapeutics
5/31/2023
Mission Bio, Inc. today announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications.
-
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets
5/31/2023
Altamira Therapeutics Ltd. (NASDAQ:CYTO) today announced the publication of a peer-reviewed article in the International Journal of Molecular Sciences (IJMS) reviewing the challenges in the safe and effective delivery of RNA molecules to target cells beyond the liver.
-
ImmPACT Bio to Present at the 2023 Jefferies Healthcare Conference
5/23/2023
ImmPACT Bio USA, Inc. today announced that it will participate at the 2023 Jefferies Healthcare Conference, to be held from June 7-9, 2023, in New York.
-
Medigene AG Expands Patent Portfolio for its End-to-End Platform
5/22/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor.
-
Tevogen Bio will Present Positive Proof-of-Concept Trial Findings at the 5th Annual Allogeneic Cell Therapies Summit in Boston, MA
5/22/2023
Tevogen Bio is pleased to announce that it will present the proof-of-concept clinical trial results of TVGN 489, the company's first clinical product from its ExacTcell platform, at the 5th Annual Allogeneic Therapies Summit in Boston, MA.
-
NeuBase Announces Formation of Gene Editing Advisory Board
5/16/2023
NeuBase Therapeutics, Inc. announced the formation of a gene editing advisory board comprised of distinguished leaders of the scientific community who will support the development of the differentiated gene editing capabilities of the Company’s PATrOL™ platform.
-
ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
5/15/2023
ImmPACT Bio USA, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for IMPT-314, a potential first-in-class CD19/CD20 CAR T therapy for the treatment of patients with B-cell mediated malignancies.
-
ImmPACT Bio to Present at the 2023 RBC Capital Markets Global Healthcare Conference
5/10/2023
ImmPACT Bio USA , Inc. today announced that it will participate at the 2023 RBC Capital Markets Global Healthcare Conference, to be held from May 16-17, 2023.
-
ORYZON to Give Updates on Corporate Progress in May-June 2023
5/9/2023
Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events on May-June.
-
ImmPACT Bio Announces Opening of California-Based GMP Facility for Clinical Production of IMPT-314, a CD19/CD20 CAR T Therapy for B-Cell Malignancies and Autoimmune Diseases
5/8/2023
ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced the opening of the Company's 21,500 square foot Good Manufacturing Practices (GMP) facility in Los Angeles, California.
-
Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors
5/2/2023
Medigene AG reports it has partnered with Helmholtz Munich to acquire the exclusive, worldwide rights to the CD40L-CD28 costimulatory switch receptor adding to the portfolio of technologies within Medigene’s end-to-end platform.